Harbour BioMed has appointed Youchen Chen and Dr. Ian Y. Liu to its board of executive directors. The leadership changes aim to strengthen the company’s strategic direction and operational oversight.

Harbour BioMed has officially appointed Youchen Chen and Dr. Ian Y. Liu to its board of executive directors, a leadership change intended to strengthen the company’s strategic direction and operational oversight.

China’s Harbour BioMed has signed a deal worth over US$1.2 billion with a clinical-stage biotechnology company to develop and commercialize an antibody outside China, reflecting a growing trend of such pacts by Chinese drug makers.